|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.9 USD | -1.45% |
|
-6.18% | -22.50% |
| Apr. 24 | Arvinas, Inc. Appoints Randy Teel as Chief Business Officer | CI |
| Apr. 15 | H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating | MT |
April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas for the U.S. drug developer's experimental prostate cancer drug, Arvinas said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 88.87 CHF | -0.70% | +1.73% | 200B | ||
| 31.9 USD | -1.45% | -6.18% | 2.21B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -22.50% | 2.21B | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
ARVINAS, INC. 
